

RECEIVED

#10

APR 20 2005

TECH CENTER 1600/2900

Patent
226/104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:) Group Art Unit: 1632
Bradford Duft al.)
Serial No.: 08/870,762)
Filed: June 6, 1997)
For: METHODS FOR TREATING)
OBESITY)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.97-98, the following information is brought to the attention of the Examiner. The patents are listed on the attached Form PTO-1449 and copies are enclosed for the convenience of the Examiner.

I certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office (PCT Search Report attached

SD-98546.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

December 24, 1998
Date of Deposit

Jeanne M. Snyder

Name of Person Mailing Paper

Jeanne M. Snyder
Signature of Person Mailing Paper

hereto) in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

The items identified in this Supplemental Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" §102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

No fee is believed due in connection with this Supplemental IDS, however, if any fee is due please charge Deposit Account No. 12-2475 for the appropriate amount.

Respectfully submitted,

LYON & LYON LLP

Dated: December 24, 1998

By: Sheryl R. Silverstein
Sheryl R. Silverstein
Reg. No. 40,812

SRS:jms
633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(213) 489-1600

FORM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
226/104SERIAL NO.
08/870,762APPLICANT:
Bradford Duff et al.FILING DATE:
June 6, 1997GROUP:
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	5,175,145	12/29/92	Cooper			
	AB	5,234,906	8/10/93	Young et al.			
	AC	5,364,841	11/15/94	Cooper et al.			
	AD	5,656,590	8/12/97	Rink et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AE	Kolterman et al., "Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue," <u>Diabetes Care</u> 18(8):(Abstract) (1995)
	AF	Kong et al., "Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM," <u>Diabetologia</u> 40(1):82-88 (1997)
	AG	Kong et al., "The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM," <u>Diabetologia</u> 41(5):577-583 (1998)
	AH	Nyholm et al., "Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus," <u>J. Clin. Endocrinol. Metab.</u> 81(3):1083-1089 (1996)
	AI	Schmitz et al., "Effects of amylin and the amylin agonist pramlintide on glucose metabolism," <u>Diabetic Med.</u> 14(2):S19-S23 (1997)
	AJ	Thompson et al., "Effects of 4 weeks' administration of pramlintide; a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations," <u>Diabetologia</u> 40(11):1278-1285 (1997)
	AK	Thompson et al., "Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes," <u>Diabetic Med.</u> 14(7):547-555 (1997)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.